Muna Therapeutics announced on 4 June 2026 that a study led by collaborators across Europe was published in Nature Medicine, reporting that microglial state transitions play a central role in Alzheimer’s disease.
The research used Muna’s MiND-MAP platform together with spatial transcriptomics and single-cell methods to map brain environments and to show that disease progression depends not only on amyloid and tau accumulation but on how microglia respond to those pathologies.
A key finding was the identification of a tipping point where microglia shift from an early, potentially protective inflammatory state to a later phenotype associated with tau pathology and neurodegeneration.
The early protective response was found to be enriched for TREM2-related signaling, a pathway genetically linked to Alzheimer’s risk and the primary target of Muna’s Phase 1 clinical candidate MNA-001, which the company claims is a potent, selective, orally administered small molecule.
The study also observed that cognitively intact individuals, including centenarians, may avoid harmful microglial transitions or uncouple microglial activation from tau accumulation, a result the company says supports its strategy to enhance innate neuroprotection as it advances MNA-001 through Phase 1 testing.
